Scarica l'app Stockscreener
3.64
6.74%
0.23
Dopo l'orario di chiusura:
3.65
0.010
+0.27%
Precedente Chiudi:
$3.41
Aprire:
$3.44
Volume 24 ore:
590.30K
Relative Volume:
0.79
Capitalizzazione di mercato:
$172.15M
Reddito:
$144.98M
Utile/perdita netta:
$-104.19M
Rapporto P/E:
-1.5378
EPS:
-2.367
Flusso di cassa netto:
$-82.90M
1 W Prestazione:
+11.31%
1M Prestazione:
+39.46%
6M Prestazione:
-3.96%
1 anno Prestazione:
-35.58%
Intervallo 1D:
$3.44
$3.69
Intervallo di 1 settimana:
$3.23
$3.72
Portata 52W:
$2.15
$8.77
Quanterix Corp Stock (QTRX) Company Profile
Nome
Quanterix Corp
Settore
Industria
Telefono
617-301-9400
Indirizzo
900 MIDDLESEX TURNPIKE, BILLERICA, MA
Compare QTRX vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QTRX
Quanterix Corp
|
3.64 | 154.65M | 144.98M | -104.19M | -82.90M | -2.367 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Quanterix Corp Stock (QTRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-02-01 | Iniziato | Scotiabank | Sector Outperform |
| 2023-09-25 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-08 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-05-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-15 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-08-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-08-09 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-03-02 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-04 | Iniziato | Goldman | Sell |
Mostra tutto
Quanterix Corp Borsa (QTRX) Ultime notizie
Quanterix Corporation Launches PhenoCode 2.0 Molecular Barcoding Kit, Confirms TIME And High-Plex ADC Panels For Fourth Quarter Shipment, And Opens Custom ADC Panel Development - marketscreener.com
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026 - marketscreener.com
Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Quanterix Corp (NASDAQ: QTRX) Grants 260,315 Derivative Securities to Chief Commercial Officer Gute James Edward Jr. - Kalkine Media
Quanterix (QTRX) awards its CCO 260K RSUs - Stock Titan
Quanterix CTO Michael Francis Executes 1,558 Stock Options and Forfeits 467 Shares on September 15, 2026 - kalkinemedia.com
365,326 stock units go to two new employees at Quanterix. They vest over four years. - Stock Titan
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Quanterix (QTRX) CTO converts RSUs, withholds shares for taxes - Stock Titan
Quanterix Corporation Announces Appointment of Dr. Yuri Fesko to Chief Medical Officer - marketscreener.com
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Quanterix (NASDAQ: QTRX) CTO uses shares to cover exercise price or taxes - Stock Titan
Bruker Corporation Executive is Named Finance Chief at Quanterix - Medical Product Outsourcing
Quanterix (QTRX) director adds 3,955 shares via RSU vest - Stock Titan
Quest Diagnostics Executive Recruited to Quanterix’s Senior Management Team - Medical Product Outsourcing
Quanterix (QTRX) CCO files initial ownership report with no shares - Stock Titan
Quanterix (QTRX) director now holds 162,401 shares - Stock Titan
Quanterix (QTRX) Q2 2026 Earnings Call Transcript - The Globe and Mail
QTRX Maintains Rating by Canaccord Genuity -- Price Target Lowered to $3.00 - GuruFocus
Quanterix (NASDAQ:QTRX) Price Target Cut to $3.00 by Analysts at Canaccord Genuity Group - MarketBeat
Canaccord cuts Quanterix stock price target on weak Q2 results - Investing.com
GSA Capital Partners LLP Makes New Investment in Quanterix Corporation $QTRX - MarketBeat
Canaccord cuts Quanterix stock price target on weak Q2 results By Investing.com - Investing.com UK
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test - sharewise.com
Quanterix (NASDAQ:QTRX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Quanterix Stock Price Forecast. Should You Buy QTRX? - StockInvest.us
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Quanterix Corp (QTRX) director-linked trusts buy 99,400 shares in open market - Stock Titan
Quanterix Corp (QTRX) Stock News Today - TradingKey
Quanterix Corp (QTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quanterix at canaccord growth conference: sales reset aims to lift growth - Investing.com
Quanterix (QTRX) Earnings Shake Up The Story As Fair Value Still Sits Higher - Yahoo Finance
QTRX Maintains Hold Rating -- Price Target Lowered to $3.00 by T - GuruFocus
TD Cowen Issues Pessimistic Forecast for Quanterix (NASDAQ:QTRX) Stock Price - MarketBeat
Quanterix earnings missed by $0.64, revenue fell short of estimates - Investing.com Canada
Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid Market Softness - GuruFocus
Earnings call transcript: Quanterix Q2 2026 revenue miss sends shares down 43% - Investing.com South Africa
Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ... - Yahoo Finance
Quanterix (NASDAQ:QTRX) Drops 39% After Outlook Revision Pushes Breakeven Back to 2027 - TechStock²
Quanterix Q2 Earnings Call Highlights - MarketBeat
Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even - Yahoo Finance
Quanterix Q2 2026 slides: revenue miss prompts guidance cut - Investing.com
Quanterix Corp (QTRX) Misses Q2 Earnings Estimates with EPS at - GuruFocus
Quanterix appoints Jim Gute as chief commercial officer - Investing.com
QTRX Looks 65.9% Undervalued on GF Value™ Despite Revenue Miss - GuruFocus
Quanterix Q2 adjusted EPS misses estimates, sales rise 34% - scanx.trade
Form 8K Quanterix Corp For: 10 August By Investing.com - Investing.com Nigeria
Quanterix (NASDAQ:QTRX) Announces Quarterly Earnings Results - MarketBeat
Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q Summary - TradingView
Quanterix (QTRX) boosts revenue as Alzheimer’s bets rise amid big write-downs - Stock Titan
Quanterix Corporation Provides Financial Guidance for the Third Quarter of 2026 - marketscreener.com
Quanterix Corp Azioni (QTRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Quanterix Corp Azioni (QTRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DONNELLY WILLIAM P | Director |
Aug 12 '26 |
Buy |
2.75 |
27,155 |
74,676 |
27,155 |
| Meadows Benjamin | Chief Commercial Officer |
May 12 '26 |
Buy |
2.77 |
3,500 |
9,695 |
3,500 |
0.26%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):